LFA-1 alpha subunit antibodies and methods of use

Abstract

Antibodies useful for and methods of treating LFA-1 alpha subunit associated physiological conditions and diseases treatable with an antibody that binds LFA-1 alpha subunit, such as HIV, are provided.

1 - 107 . (canceled)  
     
     
         108 . A composition comprising 100 mg or more S6F1, TS2/4 antibody, humanized form or subsequence thereof, and a pharmaceutically acceptable carrier.  
     
     
         109 . A composition comprising 100 mg or more fully human antibody having a binding affinity for LFA-1 alpha subunit or an epitope in LFA-1 alpha subunit within about 1 to 3, 2 to 5, 5 to 10, 10 to 50 or 10 to 100 of the binding affinity of S6F1 or TS2/4, and a pharmaceutically acceptable carrier.  
     
     
         110 . The composition of  claim 108  and  109 , further comprising instructions for administering 1.25 to 1.5, 1.5 to 1.75, 1.78 to 2.0, 2.0 to 2.5, 2.5 to 3.0, 3.0 to 5.0 mg/kg body weight of the composition, or greater, to the subject.  
     
     
         111 . A kit comprising the composition of claims  108  or  109 , said composition in a single unit dosage form for administering to a subject.  
     
     
         112 . The kit of  claim 111  comprising multiple unit dosage forms of the 100 mg or more S6F1, TS2/4 antibody, humanized form or subsequence thereof.  
     
     
         113 . The kit of  claim 112  comprising multiple unit dosage forms of the 100 mg or more fully human antibody having a binding affinity for LFA-1 alpha subunit or an epitope in LFA-1 alpha subunit within about 1 to 3, 2 to 5, 5 to 10, 10 to 50 or 10 to 100 of the binding affinity of S6F1 or TS2/4, and a pharmaceutically acceptable carrier.  
     
     
         114 . The composition of claims  108  or  109  or kit of claims  111  or  112 , wherein the composition is present in an ampule, vial, bottle or syringe.  
     
     
         115 . The composition of claims  108  or  109  or kit of claims  111  or  112 , further comprising instructions for administering greater than 1 mg/kg body weight of the composition to the subject.  
     
     
         116 . The kit of claims  111  or  112 , further comprising instructions for administering 1.25 to 1.5, 1.5 to 1.75, 1.75 to 2.0, 2.0 to 2.5, 2.5 to 3.0, 3.0 to 5.0 mg/kg body weight of the composition, or greater, to the subject.